Editas Medicine, Inc. (EDIT)
1.64
-0.07
(-4.09%)
USD |
NASDAQ |
Nov 20, 16:00
1.64
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Total Liabilities (Quarterly) : 134.89M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 134.89M |
| June 30, 2026 | 132.08M |
| March 31, 2026 | 144.93M |
| December 31, 2025 | 159.25M |
| September 30, 2025 | 188.30M |
| June 30, 2025 | 191.39M |
| March 31, 2025 | 201.23M |
| December 31, 2024 | 207.32M |
| September 30, 2024 | 151.93M |
| June 30, 2024 | 152.79M |
| March 31, 2024 | 145.95M |
| December 31, 2023 | 150.06M |
| September 30, 2023 | 144.19M |
| June 30, 2023 | 142.04M |
| March 31, 2023 | 146.63M |
| December 31, 2022 | 153.64M |
| September 30, 2022 | 116.28M |
| June 30, 2022 | 115.42M |
| March 31, 2022 | 110.35M |
| December 31, 2021 | 123.84M |
| September 30, 2021 | 130.22M |
| June 30, 2021 | 142.52M |
| Date | Value |
|---|---|
| March 31, 2021 | 142.30M |
| December 31, 2020 | 179.02M |
| September 30, 2020 | 156.00M |
| June 30, 2020 | 228.71M |
| March 31, 2020 | 232.17M |
| December 31, 2019 | 246.45M |
| September 30, 2019 | 162.37M |
| June 30, 2019 | 162.56M |
| March 31, 2019 | 161.75M |
| December 31, 2018 | 184.22M |
| September 30, 2018 | 163.18M |
| June 30, 2018 | 162.20M |
| March 31, 2018 | 156.47M |
| December 31, 2017 | 165.18M |
| September 30, 2017 | 161.34M |
| June 30, 2017 | 183.84M |
| March 31, 2017 | 188.58M |
| December 31, 2016 | 94.58M |
| September 30, 2016 | 71.98M |
| June 30, 2016 | 62.27M |
| March 31, 2016 | 47.44M |
| December 31, 2015 | 32.56M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 11.83B |
| Alnylam Pharmaceuticals, Inc. | 4.391B |
| Halozyme Therapeutics, Inc. | 3.529B |
| AVITA Medical, Inc. | 77.83M |
| Iovance Biotherapeutics, Inc. | 178.55M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 219.41M |
| Shareholders Equity (Quarterly) | 84.52M |
| Debt to Equity Ratio | 0.8372 |
| Current Ratio | 2.822 |
| Net Debt Paydown Yield | 0.36% |